Methamphetamine (MET) Rapid Test – Saliva Screening Device

A Methamphetamine Saliva Rapid Test is a drug abuse screening device used to detect methamphetamine exposure in an oral fluid specimen. Saliva testing is widely used in modern drug screening programs because it is simple to collect, non-invasive, and suitable for observed collection. The MET Saliva Rapid Test by LARKSOIS Pharma is designed for fast preliminary screening where recent exposure assessment is important.

• Saliva testing is useful because it is practical, non-invasive, and suitable for observed collection. This makes the MET Saliva Rapid Test useful in settings where sample integrity and quick testing are important.
• Oral fluid testing usually focuses on recent exposure. It may have a shorter detection window than hair testing, but it is useful for fast and convenient preliminary screening.
• The Methamphetamine Saliva Rapid Test can support workplace drug abuse screening, clinical toxicology screening, rehabilitation monitoring, forensic testing, roadside screening where permitted, and international diagnostic distribution.

The Methamphetamine (MET) Saliva Rapid Test by LARKSOIS Pharma can be used across multiple professional settings where preliminary methamphetamine screening support is required.

Applications

• Workplace drug abuse screening
• Roadside and safety-sensitive screening where legally permitted
• Occupational health and compliance testing
• Clinical toxicology screening
• Rehabilitation and recovery monitoring
• Forensic and correctional testing
• Institutional drug monitoring workflows
• International diagnostic distribution channels

The 20ng/ml cut-off means the Methamphetamine (MET) Saliva Rapid Test is designed to screen saliva specimens at this threshold. If the methamphetamine concentration in the saliva specimen meets or exceeds the cut-off level, the test may show a presumptive positive result. If the concentration is below the cut-off level, the test may show a negative result. Cut-off values help standardize screening interpretation, but rapid test results may still be affected by specimen quality, oral fluid volume, collection timing, oral contamination, test handling, storage conditions, and reading time.

• The MET Rapid Test by LARKSOIS Pharma works through a rapid immunoassay screening principle. A saliva specimen is collected according to the product insert, applied to the test device, and interpreted visually within the recommended reading time.
• The result should always be checked with the control indicator to confirm that the test has run correctly.
• The test provides a qualitative result, meaning it indicates whether methamphetamine is detected above or below the specified product cut-off.

Instructions

• A valid control indicator must appear
• A positive result is presumptive only
• A negative result does not always rule out exposure
• Results should be read only within the recommended time window
• Non-negative results should be confirmed through certified laboratory testing
• Testing should follow local laws, workplace policies, and professional protocols

Instructions

• Saliva-based methamphetamine drug abuse screening
• 20ng/ml cut-off level
• Rapid test method for preliminary detection
• Non-invasive oral fluid specimen collection
• Suitable for professional testing programs
• Useful for workplace, clinical, forensic, roadside, and rehabilitation settings
• Supports recent-exposure screening workflows
• Practical visual result interpretation
• Suitable for international diagnostic supply
• Supplied by LARKSOIS Pharma for global markets

The Methamphetamine (MET) Saliva Rapid Test uses a rapid screening method for qualitative detection of methamphetamine exposure in saliva specimens. It is designed to provide a preliminary screening result at the stated 20ng/ml cut-off.

Benefits

• Saliva-based rapid screening format
• 20ng/ml methamphetamine cut-off
• Designed for MET drug screening
• Suitable for professional diagnostic use
• Supports recent-use screening programs
• Useful for clinical, workplace, rehabilitation, forensic, roadside, and institutional workflows
• Applicable for laboratories, hospitals, diagnostic centers, and distributors
• Supports international drug screening requirements

The Methamphetamine (MET) Rapid Test is designed for saliva specimens. Saliva testing is useful where non-invasive collection, observed sampling, and quick preliminary screening are important.

Guidance

• Use saliva specimen only
• Follow the product insert carefully
• Collect saliva using the approved collection method
• Avoid sample contamination before collection
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, legal, workplace, forensic, or institutional policy

Note

Saliva testing does not prove current impairment by itself. A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

• The MET saliva rapid test plays an important role in drug-of-abuse screening because methamphetamine misuse can create health, safety, workplace, and legal concerns.
• Saliva-based screening may be selected when organizations need fast, recent-use, and observed collection-based screening support.
• For global buyers, the Methamphetamine MET Saliva Rapid Test 20ng/ml is a useful product for diagnostic portfolios, drug testing panels, rehabilitation support, workplace safety programs, roadside screening where permitted, forensic screening, and institutional monitoring applications.

Steps

• Bring the test device and saliva collection materials to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect saliva according to the approved collection method
• Apply the saliva specimen according to the test instructions
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Methamphetamine (MET) Saliva Rapid Test.

Positive

A positive or non-negative result suggests that methamphetamine may be present in the saliva specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that methamphetamine was not detected or was below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and properly collected saliva specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight and moisture
• Do not freeze the test device
• Keep the pouch sealed until use
• Do not use damaged or opened packaging
• Do not use after the expiry date
• Follow the storage temperature mentioned on the product label

Note

Proper storage helps maintain the reliability and performance of the MET saliva rapid test.

Instructions

• For professional in-vitro screening use only
• Use saliva specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Avoid sample contamination before collection
• Wear gloves and follow standard hygiene practices
• Handle all specimens as potentially infectious material
• Avoid using expired or damaged test kits
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides professional diagnostic and pharmaceutical solutions for international healthcare and screening markets. The Methamphetamine (MET) Rapid Test is developed for buyers who require a practical, reliable, and globally suitable drug abuse screening product.

Advantages

• International-quality product approach
• Professional drug of abuse rapid test portfolio
• Suitable for bulk and institutional supply
• Practical saliva-based screening format
• Distributor-friendly product range
• Focus on consistency, usability, and screening reliability
• Suitable for workplace, forensic, clinical, roadside, and rehabilitation markets